Latest News - DexCom
Top Corporates Hub
DexCom
Morgan Stanley Upgrades DexCom (DXCM), Cites Undervalued Recovery and G7 Margin Potential
22.12.2025 13:42
DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from $63. The firm noted that the company is overcoming recent operational hurdles while its stock remains at historical lows. […]
Undervalued Equities That May Offer Value In December 2025
22.12.2025 11:37
As the U.S. stock market experiences a resurgence with major indexes posting gains, driven by a rally in tech stocks, investors are increasingly looking for opportunities that may be undervalued. In this environment of renewed risk appetite and shifting sector performances, identifying stocks that offer strong fundamentals at attractive valuations becomes crucial for those seeking potential value in their portfolios.
3 Stocks Estimated To Trade At Discounts Of Up To 49.7%
19.12.2025 11:38
As the U.S. stock market experiences a notable downturn, with major indexes like the S&P 500 and Dow Jones Industrial Average posting consecutive losses amid tech sector retreats and AI bubble concerns, investors are increasingly on the lookout for opportunities in undervalued stocks. In such turbulent times, identifying stocks that are trading at significant discounts can offer potential value, especially when broader market conditions have led to price corrections across various sectors.
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Ignore
19.12.2025 04:35
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
4 Reasons Why DexCom Could Be A Good Buy For 2026
16.12.2025 07:37
Discover why DexCom (DXCM) could rebound in 2025. Explore buyback plans, growth potential, and investment insights in the evolving healthcare market.
Freshworks And Two More Stocks Estimated To Be Trading Below Fair Value
08.12.2025 11:38
As U.S. stocks rise on hopes of a Federal Reserve rate cut, the market's attention is keenly focused on inflation data and major corporate deals like Netflix's acquisition of Warner Bros. Discovery. In such an environment, identifying undervalued stocks can be crucial for investors looking to capitalize on potential opportunities, as these stocks may offer significant value relative to their current market prices amidst shifting economic conditions.
Is DexCom Stock Underperforming the S&P 500?
03.12.2025 12:59
DexCom has considerably underperformed the S&P 500 over the past year, but analysts are highly optimistic about the stock’s prospects.
Lyft And 2 Other Stocks That May Be Trading Below Fair Value Estimates
03.12.2025 11:37
As of early December 2025, U.S. markets have shown resilience with major indexes closing higher amid a rebound in tech and crypto-related stocks. This environment presents opportunities for investors to explore stocks that may be trading below their fair value estimates, such as Lyft and others, by focusing on fundamental strengths and market positioning amidst the current economic landscape.
3 Stocks Estimated To Be Trading Below Their Intrinsic Value In December 2025
02.12.2025 11:38
As December 2025 begins, the U.S. stock market faces a pullback with major indices like the Dow Jones, S&P 500, and Nasdaq closing lower amid a risk-off sentiment affecting big tech and crypto-tied shares. In such an environment, identifying stocks that are potentially trading below their intrinsic value can offer investors opportunities to capitalize on mispricings in the market.
Stock Index Futures Gain as Investors Recover Risk Appetite
02.12.2025 11:22
December S&P 500 E-Mini futures (ESZ25) are up +0.27%, and December Nasdaq 100 E-Mini futures (NQZ25) are up +0.39% this morning, signaling a rebound from yesterday’s sell-off on Wall Street as investor risk appetite gradually returns at the start of December, a period that has historically been strong for markets.
Here’s Why Dexcom (DXCM) Traded Down in Q3
27.11.2025 13:13
Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q3 2025 investor letter. A copy of the letter can be downloaded here. U.S. large-cap growth equities continued to recover from a sharp sell-off in early April. Strong corporate earnings, investor enthusiasm around artificial intelligence (AI), and growing expectations for Federal Reserve […]
Elanco, AMN Healthcare Services, Brookdale, DexCom, and Addus HomeCare Shares Skyrocket, What You Need To Know
25.11.2025 00:00
A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies.
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States
20.11.2025 13:30
SAN DIEGO, November 20, 2025--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM s
Diabetes Care Devices Markets, 2023-2024 & 2025-2033 with Abbott, Dexcom, Medtronic, Roche, Ascensia, LifeScan, Novo Nordisk, Eli Lilly, and Sanofi Leading
20.11.2025 10:51
The diabetes care devices market is driven by rising diabetes cases and demand for advanced monitoring and insulin solutions. Opportunities lie in emerging markets where lifestyle shifts increase diabetes rates, along with innovations like AI analytics and connected devices accelerating personalized care.Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The "Diabetes Care Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and For
3 Reasons We’re Fans of DexCom (DXCM)
18.11.2025 04:01
What a brutal six months it’s been for DexCom. The stock has dropped 32.6% and now trades at $58.63, rattling many shareholders. This may have investors wondering how to approach the situation.
Aristotle Atlantic’s Core Equity Strategy Initiated a Position in Dexcom (DXCM) Backed by Its Robust Financial Stability
14.11.2025 14:32
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor letter. The letter highlighted the market review, quarterly performance, and attribution analysis. A copy of the letter can be downloaded here. In the quarter, the US equity market rallied, with the S&P 500 Index reaching 8.12%. Bonds also finished higher in […]
Dexcom Reveals Global Diabetes Advocates: New Voices for Diabetes Awareness This World Diabetes Day
14.11.2025 13:00
SAN DIEGO, November 14, 2025--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom’s World Diabetes Day campaign.
Is It Time to Revisit DexCom After Latest Innovation Headlines?
13.11.2025 11:16
Ever wondered if DexCom is now a bargain or still priced for perfection? Let's get under the hood to see if the recent headlines match up with what the numbers are really saying. The stock has seen mixed momentum lately, climbing just 0.6% over the past week but still down 24.1% year-to-date and 17.8% in the past twelve months. This performance has put value-focused investors on alert. Recent news around DexCom's continued innovation in glucose monitoring technology has kept the company in...
Whoop Is Considering Going Public in the Next Two Years, CEO Says
12.11.2025 14:48
Founder and Chief Executive Officer Will Ahmed said the business is well-positioned for an IPO now that it’s broadened its portfolio to include proprietary technology, hardware, software, analytics and other items, such as accessories and apparel. While Ahmed has previously said Whoop is likely to go public, he hadn’t shared when that might happen.
Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others
12.11.2025 14:45
In the past week or so, renowned investors Carl Icahn and Mario Gabelli led some huge insider buying. These were not the only notable purchases though.